RxDoctor Payments Data

Charai Ray

Family · Drexel Hill, PANPI 1982103263

Payments from drug & device makers

$1,285in general payments, 2019–2025

Across 31 payments — averaging $41.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$442
  • Inari Medical, Inc.$238
  • Novartis$208
  • Boehringer Ingelheim$101
  • Astellas Pharma US Inc$99
  • Kestra Medical Technology Services, Inc.$62
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$1,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,285 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,297
Medicare patients
47
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan45$55,050
JardianceEmpagliflozin13$22,442
FarxigaDapagliflozin Propanediol12$10,512
Metoprolol Succinate27$492
Spironolactone43$309
Valsartan11$214
Carvedilol20$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$208$55,05045 claims
Boehringer IngelheimJardiance$101$22,44213 claims
AstraZenecaFarxiga$442$10,51212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Drexel Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →